Denali Therapeutics (DNLI) Operating Leases (2019 - 2026)
Denali Therapeutics (DNLI) posted quarterly Operating Leases of $24.7 million for Q1 2026, down 42.65% year-over-year from $43.0 million in Q1 2025, and down 9.3% quarter-over-quarter from $27.2 million in Q4 2025.
Denali Therapeutics (DNLI) Operating Leases (2019 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Operating Leases for 8 consecutive years, with $24.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 42.65% year-over-year to $24.7 million; the TTM figure through Mar 2026 stood at $24.7 million (down 42.65% YoY), while the FY2025 annual figure was $27.2 million, down 25.8% from the prior year.
- Operating Leases retreated to $24.7 million in Q1 2026 per DNLI's latest filing, from $27.2 million in the prior quarter.
- Across five years, Operating Leases topped out at $62.0 million in Q3 2022 and bottomed at $24.7 million in Q1 2026.
- Historically, Operating Leases has averaged $45.4 million across 5 years, with a median of $46.9 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Leases rose 3.43% — and 2026, when it tumbled 42.65%.
- Denali Therapeutics' Operating Leases stood at $53.0 million in 2022, then retreated by 15.18% to $45.0 million in 2023, then decreased by 18.47% to $36.7 million in 2024, then dropped by 25.8% to $27.2 million in 2025, then dropped by 9.3% to $24.7 million in 2026.
- Business Quant data shows DNLI's Operating Leases at $24.7 million in Q1 2026, $27.2 million in Q4 2025, and $29.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.03 Mn |
| Mar 31, 2026 | 24.68 Mn |
| Dec 31, 2025 | 27.21 Mn |
| Sep 30, 2025 | 29.69 Mn |
| Jun 30, 2025 | 32.11 Mn |
| Mar 31, 2025 | 43.03 Mn |
| Dec 31, 2024 | 36.67 Mn |
| Sep 30, 2024 | 46.89 Mn |
| Jun 30, 2024 | 48.75 Mn |
| Mar 31, 2024 | 43.03 Mn |
| Dec 31, 2023 | 44.98 Mn |
| Sep 30, 2023 | 53.90 Mn |
| Jun 30, 2023 | 55.53 Mn |
| Mar 31, 2023 | 57.09 Mn |
| Dec 31, 2022 | 53.03 Mn |
| Sep 30, 2022 | 62.05 Mn |
| Jun 30, 2022 | 55.53 Mn |
| Mar 31, 2022 | 57.09 Mn |
| Dec 31, 2021 | 58.55 Mn |
| Sep 30, 2021 | 59.99 Mn |